In tableting operations, ferric maltol is handled as a crystalline drug substance whose iron content of 12.95% w/w fixes the API mass at 231.7 mg for a 30 mg elemental iron dose. The material is passed through a conical mill equipped with a 500 µm grater screen to break loose agglomerates before blending. Because the drug load exceeds 40% w/w in a 500 mg tablet core, direct compression is generally restricted to the 30 mg iron strength unless a high-density filler such as calcium phosphate dibasic anhydrous is used to lower the API fraction. Dry blending in a diffusion mixer at 10–12 rpm for 20–25 min is followed by lubrication with 0.5–1.0% w/w magnesium stearate; over-lubrication above 2.0% w/w is avoided because hydrophobic film formation delays disintegration beyond the 15 min acceptance limit of Ph. Eur. 2.9.1. Compression on a rotary tablet press fitted with 10.0 mm round tooling is adjusted to produce tablet hardness in the range of 60–100 N and friability below 1.0% w/w when tested according to Ph. Eur. 2.9.7. If 60 mg elemental iron is required, the API mass rises to 463.4 mg, and a wet- or dry-granulated intermediate is preferred because direct compression blends at this drug load show insufficient flow and increased capping risk due to the large crystalline API surface area. In all tableting runs, granule loss on drying is held below 2.0% w/w and the feed frame speed is reduced to avoid particle attrition that would shift the particle size distribution and alter die filling. The hopper level on the tablet press is kept within 30–70% of capacity because higher levels can increase head pressure and cause die overfill, while lower levels increase weight variation.

What controls the dry granulation threshold when ferric maltol is roller-compacted for a 30 mg iron tablet?

Roller compaction is selected when the ferric maltol powder blend shows a compressibility index above 25% or a Hausner ratio above 1.34, measured according to Ph. Eur. 2.9.36. The compactor is configured with a ribbon thickness of 1.5–3.0 mm and roll speed of 3–6 rpm; the specific roll force is screened between 4 kN/cm and 9 kN/cm, because higher forces produce glassy ribbons that resist milling and lower forces produce friable granules with excessive fines. A ribbon density window of 1.10–1.30 g/cm³ is used as an in-process target, with density determined by envelope volume displacement on a precision balance. Ribbons are milled through a 1.0 mm conidur screen, and the resulting granule fraction between 75 µm and 500 µm is retained for compression. Fines below 75 µm are controlled to below 30% w/w; if the fines fraction exceeds this threshold, the powder blend becomes cohesive in the feed frame and produces tablets with low weight uniformity. Recycled fines are metered back at a constant ratio of 15–25% w/w to avoid process drift. The final lubricated granule is compressed within 24 h of lubrication because prolonged hold times allow magnesium stearate to redistribute and delay tablet disintegration. The dry granulation route is preferred when the API is processed in a facility without humidity control below 40% RH, because wet granulation introduces water that must be removed without destabilising the maltol ligand.

In hard-shell capsule filling of ferric maltol, the primary process constraint is powder bridging in the dosing disc rather than dissolution failure. The 30 mg elemental iron dose requires 231.7 mg of ferric maltol, which occupies a significant portion of the fill volume of a size 0 or size 1 capsule. The powder blend is prepared with lactose monohydrate or mannitol as filler, croscarmellose sodium at 2–4% w/w as disintegrant, and colloidal silicon dioxide at 0.2–0.5% w/w as flow-control agent. A dosator-type capsule filling machine is run at reduced compression settings because the crystalline ferric maltol can compact into a plug that shows slow disintegration in acidic gastric fluid if the capsule remains in the stomach longer than 30 min. Tamping-pin machines are preferred when the final blend has an angle of repose above 32°. The capsule shell is typically hypromellose; gelatin shells may show cross-linking when the fill is stored above 40°C and 75% RH, although published ferric maltol-specific data for gelatin cross-linking is limited. During automatic capsule filling, the dosing disc is set to a depth that compresses the plug to a density of 0.60–0.80 g/mL; higher plug density slows water penetration and fails disintegration. The hopper relative humidity is maintained below 40% RH because ferric maltol blends become tacky at higher moisture. The closing operation is monitored for split rate; a split rate above 0.3% triggers an adjustment of the dosing disc height or a reduction in machine speed. Metal detection is performed after filling, but the iron in ferric maltol requires calibration with a non-ferrous test coupon to avoid signal masking. In-process checks include gross fill weight and net fill weight per ICH Q2(R1), with rejection limits aligned to a ±5% fill mass allowance.

Aqueous wet granulation binder selection, granule density, and dry screening limits for ferric maltol immediate-release cores

Wet granulation is used when a 60 mg iron dose makes the direct compression core weight exceed 700 mg or when powder flow is insufficient for tablet compression. The binder is hypromellose at 3–5% w/w dissolved in purified water; the granulating fluid should be kept below 60°C to avoid surface hydration of the maltol ligand. A high-shear granulator with impeller speed 150–300 rpm and chopper speed 1,500–3,000 rpm is operated until the end-point reaches a wet mass density of 0.55–0.70 g/mL. The granulation end-point is determined by impeller torque rather than predetermined time; a torque increase of 15–25% above the dry-mix baseline corresponds to an acceptable wet mass. Use of pregelatinized starch as a binder is avoided because it can increase the viscosity of the reconstituted granule and cause slow disintegration in the stomach; hypromellose is preferred because its thermal gelation properties produce a hard granule after drying. The granulated mass is wet-milled through a 4.0 mm screen and dried in a fluid-bed dryer with inlet air at 50–60°C until the loss on drying is 1.5–2.5% w/w. Ferric maltol should not be granulated with strongly alkaline granulating fluids above pH 8.0 unless forced degradation data confirm complex integrity; alkaline pH can promote ligand dissociation and the subsequent precipitation of iron hydroxides as brown specks in the dried granule. After drying, the granule is milled through a 1.25 mm oscillating screen and the fraction above 1.25 mm is milled again. In a rotary tablet press, the granule feed is set to a paddle speed of 15–25 rpm; higher paddle speeds shear the granule and generate fines, which change the flow properties. Tablet cores produced from this granule are tested for disintegration per Ph. Eur. 2.9.1 and dissolution per USP <711> in 0.1 M hydrochloric acid at 37±0.5 °C, with sampling at 15, 30, 45, and 60 min. The dissolved iron is measured by atomic absorption or ICP-OES after immediate acidification to prevent the formation of ferric hydroxide in the dissolution medium.

When ferric maltol is formulated as oral granules for reconstitution, the suspending agent ratio and particle size upper limit control sedimentation.

Granules for oral suspension are produced when the intended population cannot swallow a capsule or tablet, or when dose titration requires flexible volume. The ferric maltol content is adjusted to deliver 10 mg or 20 mg elemental iron per graduated scoop; for 20 mg iron, the API mass is 154.4 mg. The dry blend is wet-granulated with a binder that dissolves rapidly in cold water, and the dried granule is blended with xanthan gum at 0.3–0.5% w/w as the suspending agent. The particle size of the final granule is controlled so that 90% of the mass is below 315 µm; a coarser granule settles within 2–3 min in aqueous media, while an over-milled granule below 100 µm creates a sticky sediment that adheres to the spoon. Sodium citrate dihydrate is included at 1–2% w/w as a buffering agent because tap-water pH above 8.0 can destabilise the ligand and accelerate colour change. Ascorbic acid is excluded from the granule because ferric iron can participate in redox cycling at low pH, and the resulting ferrous ion compromises the chelate; lactose monohydrate is acceptable in dry encapsulated formulations because the reaction requires water. Xanthan gum concentration is selected to give apparent viscosity of 150–400 mPa·s at 25°C when the granule is reconstituted; higher viscosity reduces resuspendability and clogs the gradient of a nasogastric tube, while lower viscosity permits sedimentation within 5 min. The granule blend is filled into sachets under nitrogen-flushed conditions if headspace oxygen exceeds 3%. Filling speed is reduced to prevent static charge from causing the granule to adhere to the laminate. Prior to use in sachets, the granule blend is filled on a form-fill-seal line with a moisture permeability limit of 0.5 g/m²/day at 38°C/90% RH for the pouch laminate. In-use stability after reconstitution is evaluated over 14 days at 2–8°C; microbiological enumeration per Ph. Eur. 5.1.4 is applied because the suspension is not preserved.

For injectable presentations, the aqueous solubility of ferric maltol is the primary limiting boundary. A parenteral iron product at 20 mg/mL elemental iron would require 154.4 mg/mL of ferric maltol in true solution, which is not achievable in water at physiological pH; the crystalline drug substance is practically insoluble in water, and the addition of organic co-solvents such as propylene glycol or PEG 300 introduces precipitation risk upon dilution in plasma. No intravenous formulation of ferric maltol is approved, and published data for this specific injectable configuration is limited. Steam sterilization at 121°C for 15 min is not considered compatible because the maltol ligand can undergo hydrolytic cleavage under autoclave load, releasing free iron that precipitates as iron hydroxide. Aseptic processing of a suspension would require particle size reduction to below 5 µm to prevent capillary occlusion, a requirement that conflicts with the crystalline particle size needed for oral powder flow and blend uniformity. Poor aqueous solubility also complicates the use of filtration as a sterility assurance step, because any colloidal iron hydroxide precipitate formed during storage would foul a 0.2 µm sterilising-grade filter. The free iron content of a parenteral trial batch is measured by ion chromatography after ultrafiltration through a 3 kDa membrane; if free iron exceeds 1% of total iron, the formulation is considered unsuitable for intravenous use due to the risk of free iron toxicity. Parenteral iron products with approved clinical data are lyophilised or aqueous colloids with a complex molecular weight above 50,000 Da; ferric maltol at 431.2 Da does not meet the colloidal size criterion required for slow iron release from the reticuloendothelial system. If a parenteral feasibility trial is undertaken, the preformulation work must include pH-solubility profiling from pH 2.0 to 8.0, test for free iron after terminal sterilization, and comply with Ph. Eur. 2.6.1 sterility and Ph. Eur. 2.9.19 particulate contamination limits for injectable volume greater than 100 mL.

Does dissolution testing of ferric maltol immediate-release products require acidification of the sampled medium to prevent iron precipitation?

Dissolution testing of ferric maltol tablet, capsule, and granule formulations is performed according to USP <711> using 900 mL of 0.1 M hydrochloric acid as the initial medium. Iron release is measured by validated atomic absorption spectroscopy or ICP-OES, not by spectrophotometric detection of the intact ferric maltol complex, because the complex may remain intact or dissociate depending on medium pH and ligand exchange with phosphate ions. If dissolution is extended into pH 4.5 acetate buffer or pH 6.8 phosphate buffer, free ferric iron can form insoluble ferric hydroxide or ferric phosphate, which can adsorb onto the filter membrane and produce low recovery. Therefore, samples are immediately acidified to pH 1.0–1.5 before filtration through a 0.45 µm PVDF syringe filter, and the first 2–3 mL of filtrate is discarded. The rinse and transfer lines are flushed with diluted hydrochloric acid after each sampling interval to avoid carry-over. Method transfer to a QC laboratory includes acidified dissolution medium at pH 1.2 with pepsin where the capsule shell dissolution is being compared; if enteric-coated granules are developed, a two-stage medium of 0.1 M hydrochloric acid for 2 h followed by pH 6.8 phosphate buffer is used, but phosphate ions can sequester ferric iron if the complex dissociates, so the pH 6.8 vessel samples are immediately complexed with excess disodium edetate before filtration to prevent adsorption. The use of disodium edetate as a masking agent is validated during method development because it may alter the absorbance if colorimetric detection is used. The dissolution method is standardised with a ferric maltol reference standard at 100% concentration in acidified medium, and the acceptance criterion is typically not less than 80% of labelled iron released at 60 min. Bioanalytical support for oral absorption studies measures total serum iron after tablet or capsule administration; the analysis uses ICP-MS with a collision cell to remove polyatomic interferences on iron-56.

Stability chambers, photoprotection, and packaging line controls for ferric maltol oral solid dosage forms

Stability evaluation follows ICH Q1A(R2) and ICH Q1B for photostability. Ferric maltol may discolour upon prolonged light exposure due to iron-ligand photoredox reactions; therefore bulk API and finished dosage forms are stored in amber glass or opaque PVC/PVDC aluminium blister cavities until confirmatory photostability data are available. The API is kept below 25°C and 60% RH unless stability data support broader conditions. Packaging line controls include a checkweigher with a rejection limit of ±2% for tablet core weight and a metal check set to reject ferrous and non-ferrous contamination above 0.5 mm; because ferric maltol itself contains iron, the metal detector threshold is routinely verified using aluminium and stainless steel test coupons at 0.8 mm to avoid masking effects. In blister packaging, the sealing temperature is maintained below 180°C when PVC-based lidding is used; excessive sealing heat can brown the contacting polymer layer and create localised moisture ingress. Storage under ICH Q1A(R2) long-term conditions at 25°C/60% RH and accelerated conditions at 40°C/75% RH is carried out in the intended packaging. For bulk API, double polyethylene bags inside a fibre drum with desiccant are used; if the desiccant capacity is exceeded, the API can show surface darkening. The packaging line uses an automated checkweigher with the tare weight stored per batch; the checkweigher is verified every 15 min using a calibrated set of test weights. The finished product specification includes an iron assay by ICP-OES, related substances by HPLC, and moisture content by Karl Fischer titration per Ph. Eur. 2.5.12, with the moisture limit set at 2.0% w/w for capsules and granules and 1.5% w/w for tablets.